SCHEMBL3270804

SCHEMBL3270804

O=C(O)COc1ccc(SCC=C(c2cccc(Cl)c2)c2cccc(Cl)c2)cc1I

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.57
TDP1 Q9NUW8 2/20 0.42
PTGDR2 Q9Y5Y4 7/20 0.42
CYP2C9 P11712 1/20 0.42
PPARG P37231 2/20 0.40
FFAR1 O14842 1/20 0.40
MAPT P10636 1/20 0.40
PTGDR Q13258 1/20 0.40
PPARA Q07869 1/20 0.39
TSHR P16473 1/20 0.39
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269680 0.98 PPARD (0.58) PPARDTDP1PTGDR2CYP2C9PPARG
SCHEMBL3269681 0.98 PPARD (0.58) PPARDTDP1PTGDR2CYP2C9PPARG
SCHEMBL3270287 0.89 PPARD (0.62) PPARDTDP1PTGDR2MAPTPTGDR
SCHEMBL3270289 0.89 PPARD (0.62) PPARDTDP1PTGDR2MAPTPTGDR
SCHEMBL3270949 0.89 PPARD (0.71) PPARDTDP1PTGDR2CYP2C9PPARG
SCHEMBL3271322 0.89 PPARD (0.53) PPARDTDP1PTGDR2FFAR1PPARA
SCHEMBL3269695 0.88 PPARD (0.66) PPARDTDP1PTGDR2MAPTPTGDR
SCHEMBL3270576 0.87 PPARD (0.72) PPARDTDP1PTGDR2CYP2C9PPARG
SCHEMBL3271335 0.87 PPARD (0.72) PPARDTDP1PTGDR2CYP2C9PPARG
SCHEMBL3270156 0.87 PPARD (0.52) PPARDPTGDR2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP claimed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US claimed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP claimed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US claimed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO claimed
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP disclosed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US disclosed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP disclosed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US disclosed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070583-A1 Novel compounds, their preparation and use PPARG, PPARD, PPARA PPARD 2/4885TDP1 3789/4885PTGDR2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.